Antidepressants may increase risk of death by 20 per cent for people with progressive lung disease
Serotonergic antidepressants increase respiratory-related adverse events for those with chronic obstructive pulmonary disease, study suggests
Publication date: Available online 21 October 2018Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Roberto Dal Negro, Edoardo Pozzi, Silvano G. CellaAbstractMucoactive drugs are commonly used in the treatment of acute respiratory tract diseases, such as lower and acute respiratory infection and chronic bronchitis (CB) or chronic obstructive pulmonary disease (COPD) in which an increased mucus secretion is one of main clinical features. Indeed these drugs are designed to promote secretion clearance and to specifically alter the viscoelastic properties of mucus, restoring an effective mucociliary clearance and redu...
Authors: Voulgaris A, Nena E, Steiropoulos P PMID: 30338831 [PubMed - in process]
Authors: Ding GZ, Li WS Abstract OBJECTIVE: Inflammatory reactions and imbalance of oxidant/antioxidant and protease/anti-protease are the major causes of chronic obstructive pulmonary disease. Based on the information mentioned, the expressions and significance of adiponectin (APN), D-dimer (DD), Interleukin (IL)-17, and high-sensitivity CRP (hs-CRP) in patients with acute exacerbation of chronic obstructive pulmonary disease were investigated in this study. PATIENTS AND METHODS: A total of 70 patients with chronic obstructive pulmonary disease were enrolled and divided into stable group (group A, 28 cases) an...
ConclusionsNIV showed a significant protective effect for intubation in immunosuppressed patients (cancer and transplants) and in patients with APE/CAP. However, the benefits of NIV for other etiologies are not clear and more trials are needed to prove these effects.
Aging Cell, EarlyView.
Publication date: Available online 18 October 2018Source: The Lancet Respiratory MedicineAuthor(s): Samy Suissa, Sophie Dell'Aniello, Pierre ErnstSummaryBackgroundLong-acting β2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are the recommended initial maintenance treatment for chronic obstructive pulmonary disease (COPD), with almost all LABAs dispensed in fixed combination with inhaled corticosteroids (LABA-ICS). We compared the effectiveness and safety of LABA-ICS versus LAMA treatment initiation as a function of blood eosinophilia, a potential biomarker of ICS effectiveness, in a real-world settin...
Publication date: Available online 18 October 2018Source: The Lancet Respiratory MedicineAuthor(s): Leonardo M Fabbri, Bianca Beghé, Alberto Papi
Combination drug relaxes airway muscles and trials show it is more effective than either of its components alone.International Approvals
Orthopnea is a symptom rather than a condition. It is a shortness of breath that only occurs when a person is lying down and usually subsides when they sit or stand up. Causes include conditions that affect the heart or lungs, such as heart failure or chronic obstructive pulmonary disease (COPD). Learn more here.
Conclusions Clinicians should consider patient age and history of stroke, peripheral vascular disease, or anxiety/panic disorders when optimizing a lower limb prosthesis users' mobility because these variables may be predictive of modest but clinically meaningful decreased prosthetic mobility. By contrast, common comorbid health conditions such as arthritis, chronic obstructive pulmonary disease, congestive heart failure, and diabetes do not seem predictive of decreased mobility among lower limb prosthesis users.